Biotech firm Celcuity reports smaller-than-expected Q1 loss

Celcuity

14/05/2026 21:11

Overview

U.S. biotech firm's Q1 adjusted EPS and adjusted net loss both beat analyst expectations

Operating expenses rose yr/yr, driven by higher employee and launch-related costs

Outlook

Celcuity expects potential FDA approval for gedatolisib in Q3 2026 and is preparing for launch

Celcuity expects cash, investments and debt facility to finance operations through 2027

Result Drivers

R&D SPENDING - Higher research and development expenses mainly due to increased employee-related and consulting costs, and manufacturing and other costs, partially offset by lower clinical trial costs

COMMERCIALIZATION COSTS - Selling, general and administrative expenses rose due to commercial headcount additions and launch-related activities

Company press release: ID:nGNX9ZlpLr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
-$0.86
-$1.05 (11 Analysts)
Q1 EPS
-$0.97
Q1 Adjusted Net Income
Beat
-$46.80 mln
-$53.44 mln (8 Analysts)
Q1 Net Income
-$52.80 mln
Q1 Operating Expenses
$50.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Celcuity Inc is $160.00, about 28.5% above its May 13 closing price of $124.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)